QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma

NCT06939855 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Bone and Soft Tissue Tumors

Interventions

DRUG: QL1706 (bispecific antibody targeting PD-1 and CLTA-4)

Sponsor

Sun Yat-sen University